Sign in Subscribe
Pharmaceutical industry

MorphoSys' HuCAL Technology Enters Clinical Trials

Strategic Insights

— 1 min read

MorphoSys AG has achieved a significant milestone in the development of its HuCAL technology, as its partner GPC Biotech AG receives regulatory clearance to conduct a phase 1 clinical trial with an anticancer antibody generated using HuCAL. This trial represents the first time a HuCAL-derived antibody will enter clinical trials in human patients, marking a crucial step in the technology's validation. The commencement of the trial will trigger a milestone payment from GPC Biotech to MorphoSys, and the fully human antibody is expected to selectively kill activated, proliferating tumor cells in patients with hematological malignancies.

Key Takeaways:

  • The HuCAL technology has achieved a significant milestone with the initiation of a phase 1 clinical trial by its partner GPC Biotech AG.
  • The trial will involve human patients in three European countries and will mark the first time a HuCAL-derived antibody is used in clinical trials.
  • The antibody is directed against a target molecule involved in various hematological malignancies, including non-Hodgkin, Hodgkin, and Burkitt lymphomas, multiple myeloma, and hairy cell leukemia.
  • Preclinical data showed the efficacy of the antibody in several in vivo cancer models, and demonstrated enhanced efficacy when administered in combination with the anticancer drug Rituxan in a non-Hodgkin's lymphoma model.
  • The target molecule is involved in the proliferation of activated, MHC class II-positive tumor cells.
  • The trial is expected to trigger a milestone payment from GPC Biotech to MorphoSys upon the first administration of the HuCAL antibody in human patients.
  • MorphoSys develops and applies technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization.

Statistics:

  • 150,000 people worldwide were affected by non-Hodgkin's lymphoma in 2003.
  • Non-Hodgkin's lymphoma is the most common form of lymphoma affecting approximately 150,000 people worldwide in 2003.
  • The clinical trial will be conducted in three European countries.

Sources:

  • MorphoSys AG, via NewsRx.com & NewsRx.net.
  • Health & Medicine Week, "MorphoSys' HuCAL Technology Enters Clinical Trials" (2005).
  • GPC Biotech AG, via NewsRx.com & NewsRx.net.
  • NewsRx.com & NewsRx.net, "MorphoSys and GPC Biotech Announce Partnership Agreement" (1999).

Read more